PLGA Porous Microspheres Co-loading Afatinib Solid Lipid Nanoparticles and Paclitaxel for EGFR Mutation Drug Resistant NSCLC
作者单位：School of Pharmaceutical Sciences Sun Yat-sen University
会议名称：《2018年第十二届中国药物制剂大会》
会议日期：2018年
学科分类：100702[医学-药剂学] 1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学]
摘 要：正Non-small-cell lung cancers（NSCLCs）,the most common lung cancers,are reported to specifically respond to the epidermal growth factor receptor（EGFR）tyrosine kinase inhibitor（TKI）.Afatinib（AFT）is the secondgeneration EGFR-TKIs and first line treatment in advanced EGFR-mutated NSCLC ***,treatment of these EGFR-TKIs poses unexpected therapeutic challenges,such as emerging of acquired